Overell, James
F. Hoffmann-La Roche AG
2 papers on CoChatORCID 0000-0002-3998-9819
Most cited papers
- Verified
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet
Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling
Cited by 942
- Verified
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Wolinsky, J. S., Arnold, D. L., Brochet, B., Hartung, H.-P., Montalban, X., Naismith, R. T., Manfrini, M., Overell, J., Koendgen, H., Sauter, A., et al. (2020) · The Lancet Neurology
Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research
Cited by 150
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free